Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Accumulated Expenses (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Accumulated Expenses for 7 consecutive years, with $26.9 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 231.53% to $26.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.9 million through Dec 2025, up 231.53% year-over-year, with the annual reading at $26.9 million for FY2025, 231.53% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $26.9 million at 4D Molecular Therapeutics, up from $9.1 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $26.9 million in Q4 2025, with the low at $1.3 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $8.0 million, with a median of $6.7 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses plummeted 32.53% in 2024, then soared 231.53% in 2025.
  • Over 5 years, Accumulated Expenses stood at $7.7 million in 2021, then fell by 26.54% to $5.7 million in 2022, then skyrocketed by 111.18% to $12.0 million in 2023, then crashed by 32.53% to $8.1 million in 2024, then skyrocketed by 231.53% to $26.9 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $26.9 million, $9.1 million, and $6.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.